OncoResponse studies the immune systems of patients who are “elite responders” to cancer immunotherapies in order to develop new treatments for a broader array of cancer patients.
Total raised: $50.5M

Investors 3

Funding Rounds 3

DateSeriesAmountInvestorsDeal News
11.09.2018Series B$40M-OncoRespon...
10.10.2016Series A$7M-OncoRespon...
--$3.5MHelsinn In...Helsinn In...

Mentions in press and media 9

DateTitleDescriptionCategoryAuthorSource
12.09.2018Term Sheet...REBOOT REPRESENTATION Good mo...--fortune.co...
11.09.2018OncoRespon...OncoResponse, a Seattle, WA-ba...USA-finsmes.co...
11.09.2018Daily fund...Packet raises $25M to accelera...-Kristin Ka...vator.tv/n...
11.09.2018OncoRespon...The company’s approach consi...--medcitynew...
10.03.2017Term Sheet...MAYBE WINTER REALLY ISN’T CO...--fortune.co...
09.03.2017OncoRespon...OncoResponse, a Houston, Texas...USA-finsmes.co...
10.10.2016OncoRespon...OncoResponse, a Houston-based ...USA-finsmes.co...
29.05.2016Immuno-Onc...OncoResponse, a Houston, TX-ba...USA-finsmes.co...
01.01.1970Helsinn In...---helsinninv...